Indeed, at four weeks post-tumor injection, mice depleted of CD4+ or CD8+ cells developed tumors, unlike MOC2-CIITA-injected mice, where 25% of the animals remained tumor-free (Figure 8A). This evidence concerns the gene CD8A and neoplasm.